According to GlobalData’s medical device pipeline database, 829 Neuromodulation Devices devices are in various stages of development globally. GlobalData’s report Neuromodulation Devices provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 512 are in active development, while the remaining 330 are in an inactive stage of development. There are 221 products in the early stages of development, and the remaining 291 are in the late stages of development.
Neuromodulation devices are medical devices that are used to treat various neurological and psychiatric disorders by modulating the activity of the nervous system. Neuromodulation Devices work by delivering electrical or magnetic stimulation to targeted areas of the nervous system. Neuromodulation devices offer an alternative to traditional treatments for neurological and psychiatric disorders, such as medications and surgery. Deep brain stimulators (DBS), gastric electric stimulators (GES), leads, sacral nerve stimulators (SNS), spinal cord stimulators (SCS), peripheral nerve stimulators (PNS) and vagus nerve stimulators (VNS) are the segments covered under this category. One unit refers to One neuromodulation device.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Neuromodulation Devices pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Neuromodulation Devices devices. Overall, most of these Neuromodulation Devices pipeline devices are being developed by private entities.
Key players involved in the active development of Neuromodulation Devices include Stanford University, Stanford University, Nevro, ElectroCore, Medtronic, Brainsway, Hangzhou Shenluo Medical Technology, LivaNova, Neurosigma and St. Jude Medical.
For a complete picture of the developmental pipeline for Neuromodulation Devices devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
